BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

NCT03363347 · clinicaltrials.gov ↗

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Redifferentiation with retinoid acid

Sponsor

Heidelberg University